CKMT2

Across TCGA pan-cancer cohorts, CKMT2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of CKMT2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where CKMT2 RNA is repressed in tumor relative to normal tissue. In most cancer types CKMT2 is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.

KIRP, KIRC, and STAD are the cancer types where CKMT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CKMT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	All	−3.127	<.001	11	view →
KIRC	Male	II,III,IV	−2.392	<.001	10	view →
STAD	All	III,IV	−2.138	<.001	10	view →
HNSC	Male	IV	−3.397	<.001	8	view →
BLCA	Male	III,IV	−2.384	<.001	8	view →
LUSC	Male	II,III,IV	−0.732	<.001	8	view →
KICH	All	All	+1.892	<.001	7	view →
BRCA	All	III,IV	−1.909	<.001	6	view →
UCEC	All	III,IV	−1.502	<.001	6	view →
COAD	All	II,III,IV	+1.349	<.001	6	view →
THCA	Male	III,IV	−1.914	.001	4	view →
LIHC	All	All	+0.659	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

CKMT2–KIRP

Open the KIRP breakdown →